Nutralife Biosciences Stock Performance
| NLBS Stock | USD 0.0001 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Nutralife Biosciences are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nutralife Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental drivers, Nutralife Biosciences is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 742.00 | |
| Total Cashflows From Investing Activities | -675 K |
Nutralife |
Nutralife Biosciences Relative Risk vs. Return Landscape
If you would invest 0.01 in Nutralife Biosciences on September 12, 2024 and sell it today you would earn a total of 0.00 from holding Nutralife Biosciences or generate 0.0% return on investment over 90 days. Nutralife Biosciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Nutralife, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nutralife Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nutralife Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Nutralife Biosciences, and traders can use it to determine the average amount a Nutralife Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NLBS |
Based on monthly moving average Nutralife Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nutralife Biosciences by adding Nutralife Biosciences to a well-diversified portfolio.
Nutralife Biosciences Fundamentals Growth
Nutralife Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Nutralife Biosciences, and Nutralife Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nutralife Pink Sheet performance.
| Return On Equity | -14.26 | |||
| Return On Asset | -0.28 | |||
| Operating Margin | (3.80) % | |||
| Current Valuation | 11.61 M | |||
| Shares Outstanding | 176.62 M | |||
| Price To Book | 85.51 X | |||
| Price To Sales | 14.09 X | |||
| Revenue | 626.62 K | |||
| EBITDA | (5.71 M) | |||
| Cash And Equivalents | 51.8 K | |||
| Total Debt | 10 K | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (487.39 K) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 4.85 M | |||
About Nutralife Biosciences Performance
Assessing Nutralife Biosciences' fundamental ratios provides investors with valuable insights into Nutralife Biosciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Nutralife Biosciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
NutraLife BioSciences, Inc., together with its subsidiaries, engages in the development, manufacture, and distribution of nutraceutical, dietary, wellness, and cannabidiol products. NutraLife BioSciences, Inc. was incorporated in 2010 and is based in Coconut Creek, Florida. Nutralife Biosciences operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 12 people.Things to note about Nutralife Biosciences performance evaluation
Checking the ongoing alerts about Nutralife Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Nutralife Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nutralife Biosciences generated a negative expected return over the last 90 days | |
| Nutralife Biosciences has some characteristics of a very speculative penny stock | |
| Nutralife Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Nutralife Biosciences currently holds 10 K in liabilities. Nutralife Biosciences has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nutralife Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Nutralife Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nutralife Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nutralife to invest in growth at high rates of return. When we think about Nutralife Biosciences' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 626.62 K. Net Loss for the year was (5.83 M) with profit before overhead, payroll, taxes, and interest of 83.59 K. | |
| Nutralife Biosciences currently holds about 51.8 K in cash with (487.39 K) of positive cash flow from operations. | |
| Roughly 46.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Nutralife Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nutralife Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Nutralife Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nutralife Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nutralife Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nutralife Biosciences' pink sheet. These opinions can provide insight into Nutralife Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nutralife Pink Sheet Analysis
When running Nutralife Biosciences' price analysis, check to measure Nutralife Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nutralife Biosciences is operating at the current time. Most of Nutralife Biosciences' value examination focuses on studying past and present price action to predict the probability of Nutralife Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nutralife Biosciences' price. Additionally, you may evaluate how the addition of Nutralife Biosciences to your portfolios can decrease your overall portfolio volatility.